Dai­ichi Sankyo gets US patent of­fice to restart re­view of Seagen patent

Dai­ichi Sankyo is go­ing back af­ter Seagen in the lat­est bout of patent in­fringe­ment ac­cu­sa­tions.

The Japan­ese phar­ma an­nounced Fri­day that the US Patent and Trade­mark Of­fice (PTO) has agreed to the com­pa­ny’s re­quest to restart a post-grant re­view of a Seagen patent.

A post-grant re­view (PGR) is when the patent of­fice’s board — called the Patent Tri­al and Ap­peal Board — ex­am­ines at least one claim from an ex­ist­ing patent in a bid to de­ter­mine if that claim is ca­pa­ble of be­ing patent­ed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.